Bridging the Diagnostic Gap in Neurofibromatosis Type 1: When to Consider NF1 cDNA Sequencing
Pediatric Dermatology · 2026
DOI: 10.1111/pde.70257 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Dermatology, 2026. Verfasst von Brent J Doolan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Dermatology, the Hospital for Sick Children, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Neurofibromatosis 1, Neurofibromin 1. Die Arbeit nennt 9 Literaturangaben. Gefördert von: Paul and Gina Godfrey Initiative for Genomic Medicine, 2025 Ellison-Cliffe Travelling Fellowship from the Royal Society of Medicine (United Kingdom).
Abstract (Originalsprache)
Molecular confirmation of neurofibromatosis type 1 (NF1) is essential for accurate diagnosis, reproductive counseling, and lifelong surveillance, yet genomic DNA (gDNA)‐based next‐generation sequencing (NGS) panels may miss deep intronic or complex structural variants. We report five children meeting the 2021 NF1 clinical diagnostic criteria who had negative DNA‐based NGS testing but were subsequently diagnosed using NF1 cDNA‐based testing ( NF1 cDNA testing), which identified three deep intronic variants, one 5′UTR variant, and one exonic insertion, including three novel variants. Four of the five variants produced abnormal‐to‐normal transcript ratios of approximately 1:1, consistent with complete loss of normal transcript from the affected allele. These variants, detected by NF1 cDNA testing, are predicted to result in the same clinical phenotype and natural history as NF1 exonic variants, underscoring the value of NF1 cDNA testing as a second‐tier test when clinical suspicion remains high despite negative gDNA‐based tests.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Dermatology, the Hospital for Sick Children, Toronto, Ontario, Canada.
- Division of Clinical and Metabolic Genetics, the Hospital for Sick Children, Toronto, Ontario, Canada.
- Medical Genomics Laboratory, Department of Genetics, University of Alabama at Birmingham, Birmingham, Alabama, USA.
- Department of Paediatrics, University of Toronto, Toronto, Ontario, Canada.
- Child Health Evaluative Sciences, Peter Gilgan Centre for Research and Learning, the Hospital for Sick Children, Toronto, Ontario, Canada.
- Genetics & Genome Biology Program, Peter Gilgan Centre for Research and Learning, the Hospital for Sick Children, Toronto, Ontario, Canada.
ORCID-Profile: Brent J Doolan, Minu J Chiramel, Yunjia Chen, Irene Lara-Corrales, Yiming Wang
Förderung
- Paul and Gina Godfrey Initiative for Genomic Medicine
- 2025 Ellison-Cliffe Travelling Fellowship from the Royal Society of Medicine (United Kingdom)
Zitieren
APA
Doolan, B. J., Chiramel, M. J., Hendry, M., Shugar, A., Chen, Y., Lara-Corrales, I., & Wang, Y. (2026). Bridging the Diagnostic Gap in Neurofibromatosis Type 1: When to Consider NF1 cDNA Sequencing. Pediatric Dermatology. https://doi.org/10.1111/pde.70257
Vancouver
Doolan BJ, Chiramel MJ, Hendry M, Shugar A, Chen Y, Lara-Corrales I, et al. Bridging the Diagnostic Gap in Neurofibromatosis Type 1: When to Consider NF1 cDNA Sequencing. Pediatric Dermatology. 2026. doi:10.1111/pde.70257
BibTeX
@article{Doolan2026,
author = {Doolan, Brent J and Chiramel, Minu J and Hendry, Mitch and Shugar, Andrea and Chen, Yunjia and Lara-Corrales, Irene and Wang, Yiming},
title = {Bridging the Diagnostic Gap in Neurofibromatosis Type 1: When to Consider NF1 cDNA Sequencing},
journal = {Pediatric Dermatology},
year = {2026},
doi = {10.1111/pde.70257}
}
EUVIMED